On the day that Gilead introduced its new $94,500 hepatitis C drug, Harvoni, Gilead Vice President of Investor Relations Patrick O’Brien went into full spin mode, telling Politico (subscription required) that Harvoni is a bargain compared to Gilead’s other hep C drug, the $84,000 Sovaldi.

Gilead should be commended for taking action to make their best-selling treatment for Hepatitis C, Sovaldi, available to more people around the world. In India, they’ve struck licensing agreements with generic firms to produce the product for pennies on the dollar. Unfortunately, Gilead’s largess is being funded largely on the backs of American families.

Yesterday’s blockbuster earnings announcement from Gilead underscores how much room the drug manufacturer has to lower the price of its Hepatitis C drug Sovaldi.  In fact, nearly all of Gilead’s profits came from its U.S. sales of Sovaldi. The $3.48 billion that Gilead earned from sales of Sovaldi in the second quarter is only going […]

Statement from the National Coalition on Health Care’s President and CEO John Rother on the latest quarterly earnings report from Gilead Sciences, Inc., manufacturer of the hepatitis C drug Sovaldi:   “It’s clear Gilead has plenty of room to reduce the $1000 per pill price in order to ensure patients have access to this critical […]